Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Does the Forecast Indicate for the Extended-Release Drugs Market From 2025 to 2029?

In recent years, the market size for extended-release drugs has seen substantial growth. It is anticipated that it will increase from $63.11 billion in 2024 to reach $69.63 billion in 2025, with a compound annual growth rate (CAGR) of 10.3%. Factors like enhanced patient compliance, the predominance of chronic illnesses, improved effectiveness, patent protection strategies, and biodegradable implants have contributed to this growth in the historic period.

In the coming years, the extended-release drugs sector is predicted to witness swift expansion, with projections that it will escalate to $111.26 billion by 2029, boasting a compound annual growth rate (CAGR) of 12.4%. The projected increase for this period can be accounted for by factors such as the implementation of personalized medicine strategies, a patient-focused approach to drug development, a rise in diseases related to lifestyle choices, drug repurposing, and global provision of extended-release treatment options. Furthermore, essential trends expected during the forecast period encompass innovation in pharmaceuticals, progress in drug delivery system technology, advancements in nanotechnology, the application of 3D printing in drug formulations, the employment of artificial intelligence, and environmental sustainability.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12675&type=smp

What Elements Are Contributing To Growth In The Extended-Release Drugs Market?

The extended-release drug market is likely to experience growth due to a rise in chronic conditions. These chronic conditions are defined as ailments that sustain for more than a year, requiring consistent medical treatment or affecting routine activities, or even both. Such conditions include heart disease, cancer, obesity, diabetes, among others. Extended-release drug delivery systems have been engineered to keep the medication levels in the body nearly stable for an extended period. This helps in maintaining a regular therapeutic effect and prevents the drug levels from fluctuating as seen in immediate-release drugs. For example, the National Center for Biotechnology Information (NCBI), which is a US-based National Library of Medicine, predicted in January 2023 that by 2050, the population aged 50 years and above with at least one chronic illness will see an approximate 99.5% growth, increasing to 142.66 million people. Therefore, the rise in chronic conditions is a key driver fueling the growth of the extended-release drug market.

Which Segments Are Detailed In The Global Extended-Release Drugs Market Report?

The extended-release drugs market covered in this report is segmented –

1) By Type: Sustained Release Drug, Controlled Release Drug

2) By Mode: Over-The-Counter, Prescription

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores

Subsegments:

1) By Sustained Release Drug: Matrix Systems, Coating Systems

2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems

Which Emerging Trends And Strategic Shifts Are Shaping The Extended-Release Drugs Market?

The development of innovative products is a rising trend in the extended-release drug market, helping key companies maintain their market standing. For example, Zydus Pharmaceuticals (USA) Inc., a generic pharmaceutical manufacturing firm based in the U.S., unveiled Topiramate extended-release capsules for epilepsy treatment in July 2022. Prior to this, the U.S. Food and Drug Administration had given its approval for the company to bring Topiramate extended release capsules, USP 25 mg, 50 mg, and 100 mg to the market. It is the pioneer firm in the U.S. to gain final endorsement and roll out Topiramate extended-release capsules. These capsules are approved to be used in two different ways for patients suffering from partial onset or primary generalized tonic-clinic seizure.

Who Are The Key Contributors To Growth In The Extended-Release Drugs Market?

Major companies operating in the extended-release drugs market include Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Eastman Chemical Company, Catalent Pharma Solutions Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Hisamitsu Pharmaceutical Co. Inc., Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Ardena Holding NV, UPM Pharmaceuticals Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Lavipharm Laboratories Inc., Watson Pharmaceuticals Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report

Which Region Is Projected To Lead The Extended-Release Drugs Market By 2025?

North America was the largest region in the extended-release drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12675&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model